207_Combined course Presentations

ACCORD 12/0405

CAO/ARO/ AIO-04

NSABP R-04

Endpoint

STAR-01

PETACC-6 FOWARC

PCR

16% both arms

14% vs 19%

12.8% vs 16.5% (p=0.038)

19% vs 21%

11.5% vs 13%

14% vs 27.5%

CRM

4% vs 7%

8% vs 13%

5% vs 6% No data

2% vs 2%

9.2% vs 10% R1/R2

yp Node + (stage III)

29% vs 26%

30% vs 26%

27% vs 26% Not

27% vs 26%

19.9% vs 12.6%

stated

Oxaliplatin Phase III trials: Control arm in red